SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending amidst a sharp price decline that has pushed it below key support levels, igniting fervent debate within the community; bears are proclaiming a "death spiral" and predicting much lower prices, while others see it as a generational buying opportunity in the ongoing "crypto winter."

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending following a steep price drop driven by broader crypto market weakness, notably Bitcoin's decline; the community is actively debating whether this is an institutional "buy the dip" opportunity or a further crash, with some even discussing the highly speculative "Epstein files" as a contributing factor.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending due to Bitcoin's sharp price decline, which has deepened the company's unrealized losses on its significant crypto holdings, fueling intense community debate over potential "liquidation" or "bankruptcy" while others see a "buy the dip" opportunity ahead of its anticipated earnings.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst sharp debate following its launch of a multi-cancer early detection test and its aggressive stance in the weight-loss medication market. Bulls anticipate significant growth from these initiatives, viewing current price action as an oversold opportunity and potential short squeeze, while bears are exasperated by persistent selling and concerns over competitive dynamics.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst a significant downturn in the cryptocurrency market, particularly Bitcoin, which is heavily impacting the stock as the community actively debates its strong correlation to digital assets and anticipates upcoming earnings.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending after strong Q4 earnings, notably robust growth in Google Cloud and Search driven by AI, yet the market is debating its significantly increased capital expenditure guidance for 2026, with some seeing it as a strategic investment for AI dominance and others as an overextension.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending lower amid worse-than-expected jobless claims data and a broad sell-off in tech and software stocks, fueled by community debate over the high capital expenditures and uncertain returns on AI investments. The market is also reacting to a significant drop in Bitcoin, seen as a risk-off signal, as participants assess whether tech valuations are sustainable or if further downside is likely.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending as the community eagerly awaits an imminent Japan PMDA approval for its innovative Alpha DaRT cancer treatment, fueled by strong pancreatic cancer trial data, growing institutional interest, and a widespread belief that the stock is significantly undervalued and poised for a major breakout.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following its Q4 earnings beat, which showed improved profitability, positive free cash flow, and a new share repurchase authorization, prompting many to expect a substantial rebound. However, mixed analyst ratings and ongoing concerns about user growth in core markets temper investor sentiment.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending due to widespread anticipation for its upcoming earnings report, with community sentiment sharply divided on whether strong AWS cloud growth driven by AI investments and holiday sales can offset concerns over significant capital expenditures and broader tech market volatility.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stock Index Futures Climb on Trump Tariffs Report, U.S. PPI Data and Fed Speak in Focus

March S&P 500 E-Mini futures (ESH25) are up +0.49%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.67% this morning as a report indicating the U.S. might take a gradual approach to hiking tariffs boosted sentiment, while investors awaited crucial producer inflation data and comments from Federal Reserve officials.

Intra-Cellular Therapies' stock (ITCI) surged over 35% in premarket trading on Monday, poised for its best-ever open and a record high, even as broader market futures grappled with weak tech stock performance.&nbsp;The biotech firm announced it would be acquired by Johnson &amp; Johnson (JNJ) in a $14.6 billion cash deal, valuing ITCI shares at $132 each,&nbsp;which represents about 40% premium to previous close.The transaction, funded through a mix of cash and debt, is expected to close later this year, subject to shareholder and regulatory approvals. Once completed, ITCI shares will be delisted from the Nasdaq.&nbsp;Johnson &amp; Johnson plans to maintain its capital allocation strategy, including R&amp;D investment, dividends, and strategic share buybacks.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ITCI_sentiment_and_message_volume_Jan_13_premarket_42a2cd35bb.png" alt="ITCI sentiment and message volume Jan 13 premarket.png" width="1318" height="324"><figcaption>ITCI sentiment and message volume Jan 13 premarket as of 7:40 am ET | source: Stocktwits</figcaption></figure>Following the announcement, sentiment for ITCI on Stocktwits turned 'extremely bullish,' and the stock became one of the platform's top 20 trending symbols.&nbsp;Some retail investors speculated that J&amp;J secured a bargain deal amid a flurry of positive chatter.<stembedurl>https://stocktwits.com/manymore/message/599736216</stembedurl><stembedurl>https://stocktwits.com/megamaven/message/599767133</stembedurl>Shares of J&amp;J, meanwhile, were flat premarket Monday following a more than 2% dip over the last week, with retail sentiment on Stocktwits turning 'bullish.’ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in 2023.The company recently reached a favorable patent settlement with Sandoz, ensuring no generic Caplyta will launch until 2040. Analysts at BofA Securities raised ITCI's price target to $118 on Sunday, citing the settlement's positive implications.<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/32a4bb19-5f28-4ea7-a9c8-a776ef2fecd9">According</a> to the Financial Times, the deal highlights J&amp;J's strategic response to looming patent cliffs, including its projected $17 billion revenue loss when its Darzalex treatment for rare blood cancers loses exclusivity in 2029.The report added that the acquisition marks a bright spot for the biotech sector, which saw M&amp;A activity plunge in 2024. Pharma companies spent $45 billion across 30 deals — nearly half the prior year's total.ITCI stock gained 12.7% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism

ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in 2023.

Equity

J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

Intra-Cellular Therapies Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMZN earnings on Thursday?

ITCI
Intra-Cellular Therapies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ITCI News

ITCIIntra-Cellular Therapies Inc